VNDA vs CBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VNDA Captures Institutional Edge (2โ2 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vanda Pharmaceuticals Inc. (VNDA) driven by superior Valuation, Growth & Margin while CBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, VNDA trades at 103.1x Forward P/E with -77.6% operating margin (+24.1% YoY revenue) versus CBIO at N/M Forward P/E and -1432.6% operating margin (+0.0% YoY). In options structure, VNDA sits in BREAKDOWN (75th %ile IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VNDA Revenue | CBIO Revenue | VNDA Op. Margin | CBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $190M | N/A | 11.3% | N/A | VNDA |
| FY2019 | $230M | N/A | 10.0% | N/A | VNDA |
| FY2020 | $250M | $10M | 11.0% | -506.8% | VNDA |
| FY2021 | $270M | $0M | 15.7% | -5470.7% | VNDA |
| FY2022 | $250M | $0M | 2.5% | -63204.4% | VNDA |
| FY2023 | $190M | $0M | -7.2% | -392752.9% | VNDA |
| FY2024 | $200M | N/A | -20.5% | N/A | VNDA |
| FY2025 | $220M | $10M | -70.0% | -1407.5% | VNDA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VNDA | CBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $238.9M | $533.8M | Larger Scale | CBIO |
| Trailing P/E Ratio Valuation | 103.1x | N/M | Lower Multiple | VNDA |
| Forward P/E Ratio Valuation | 103.1x | N/M | Lower Multiple | VNDA |
| Revenue Growth (YoY) Growth | +24.1% | +0.0% | Higher Growth | VNDA |
| Operating Margin (TTM) Profitability | -77.6% | -1432.6% | Higher Margin | VNDA |
| Net Profit Margin Profitability | -119.9% | 0.0% | Higher Margin | CBIO |
| Return on Equity (ROE) Capital Efficiency | -82.5% | -160.8% | Higher ROE | VNDA |
| 52-Week Range Position Momentum | 4% ($4โ$10) | 24% ($9โ$27) | Stronger Trend | CBIO |
| Beta / 30D Volatility Risk Regime | 1.25ฮฒ ยท 61% Vol | 1.42ฮฒ ยท 63% Vol | Lower Realized Risk | VNDA |
| Unified Institutional Score Composite Signal | 49.0 / 100 (HOLD) | 37.4 / 100 (SELL) | Higher Composite | VNDA |